Strategies to enhance thymus-independent T cell development in cancer patients
增强癌症患者胸腺独立 T 细胞发育的策略
基本信息
- 批准号:8517047
- 负责人:
- 金额:$ 12.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-10 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adoptive TransferAdultAllogenicAntigen-Presenting CellsAntigensBiocompatible MaterialsBloodBlood CellsBone MarrowBone Marrow Stem CellCancer PatientCell Culture TechniquesCell Differentiation processCell LineageCell TherapyCellsChestClinicalCommitCritiquesDataDevelopmentDrug ControlsDrug Delivery SystemsEducational process of instructingEngineeringEngraftmentEpitheliumExtracellular MatrixGenerationsGlandGoalsGrowth FactorHematopoietic Stem Cell TransplantationHematopoietic stem cellsHigh Dose ChemotherapyImmuneImmune System PartImmune systemImmunityImmunodeficiency and CancerImmunologic MonitoringImmunosuppressionImmunotherapeutic agentImmunotherapyImplantIn VitroIndividualInfectionInflammatory ResponseK-Series Research Career ProgramsLaboratoriesLeftLifeLymphoidMalignant NeoplasmsMature T-LymphocyteMethodsMicroscopicMusNatural regenerationOrganOutcomePatientsPediatric Hematology/OncologyPhenotypePhysiciansPhysiological ProcessesPlantsPolymersPositioning AttributePropertyRadiationRadiation therapyRecurrenceRegenerative MedicineResearchRiskScientistSignal TransductionSimulateSiteSmall IntestinesStem cell transplantStromal CellsSystemT-Cell DevelopmentT-LymphocyteThymus GlandTissue EngineeringTissuesTranslational ResearchTransplantationTumor ImmunityVascularizationVirus DiseasesWritingbasebiocompatible polymerbiodegradable polymercancer cellcancer therapycancer transplantationcell growthchemotherapyclinically relevantcytokinedesignfightinghigh riskimplantationimprovedin vivoinjuredirradiationmeetingsmigrationmouse modelnanofibernotch proteinnovel strategiesprecursor cellprogramsreconstitutionresponsescaffoldstem cell nichetissue culturetraffickingtumor
项目摘要
DESCRIPTION (provided by applicant): The vast majority of T-cells are made in the thymus, a lymphoid organ that is particularly sensitive to radio- or chemotherapy. Strategies to enhance extrathymic T-cell development may therefore be useful to improve the outcome of conditions such as hematopoietic stem cell transplantation, cancer, immunosuppression or certain viral infections. I previously performed studies in mouse models of HSCT and malignancies demonstrating the feasibility and efficacy of adoptive cell therapy with ex vivo generated T cells (preT) to enhance T cell reconstitution. I found that adoptively transferred preT can be used as an "off-the-shelf" cell therapy and administered across MHC barriers to enhance thymic regeneration and T cell immunity. The main goal of this proposal is to develop strategies to enhance thymus independent T cell reconstitution in cancer patients, using tissue culture and tissue engineering based immunotherapeutic approaches. I propose to study the contribution of extrathymic sites to preT- derived T cell reconstitution, and to develop tissue constructs for T cell development ex vivo and in vivo using three-dimensional bioresorbable polymer scaffolds resembling extracellular matrix. Biodegradable polymers have the advantage that they can be used to fabricate micro or nanofibrous three-dimensional matrices for in vivo grafting, and they may be molecularly tailored to release bioactive agents resulting in highly effective localized drug delivery and control of cell growth and differentiation. T cell development will be studied in vitro and in vivo by implanting engineered stromal cell-polymer scaffold composites or cell-free thymic regeneration templates into mice followed by analysis of cell growth, differentiation, migration, and function (including anti-tumor activity). Characterization of host and biomaterial responses will also include analysis of vascularization of implants, biomaterial degradation, and inflammatory responses to implantation. Based on my preliminary data using an improved tissue engineering method with optimized design, biomaterial properties and cell-biomaterial interactions I expect that implantation of a tissue engineered artificial thymic microenvironment will result in enhanced T cell immunity and will contribute to tumor immunosurveillance. My goal over the next five years, with the help of this career development award, is to establish myself as a physician-scientist in the field of Pediatric Hematology/Oncology and to attain a tenure-track position at an academic center. As a physician-scientist, I hope to combine clinical and teaching activities with an independent laboratory-based research program with focus on clinically relevant and translational research.
描述(由申请人提供):绝大多数 T 细胞是在胸腺中产生的,胸腺是一种对放射或化疗特别敏感的淋巴器官。因此,增强胸腺外 T 细胞发育的策略可能有助于改善造血干细胞移植、癌症、免疫抑制或某些病毒感染等疾病的结果。我之前在 HSCT 和恶性肿瘤的小鼠模型中进行了研究,证明了使用离体产生的 T 细胞 (preT) 进行过继细胞治疗以增强 T 细胞重建的可行性和有效性。我发现过继转移的 preT 可以用作“现成的”细胞疗法,并跨越 MHC 屏障进行施用,以增强胸腺再生和 T 细胞免疫。该提案的主要目标是制定策略,利用基于组织培养和组织工程的免疫治疗方法,增强癌症患者胸腺独立 T 细胞的重建。我建议研究胸腺外位点对前 T 衍生 T 细胞重建的贡献,并使用类似于细胞外基质的三维生物可吸收聚合物支架来开发用于离体和体内 T 细胞发育的组织构建体。可生物降解聚合物的优点是它们可用于制造用于体内移植的微米或纳米纤维三维基质,并且它们可以进行分子定制以释放生物活性剂,从而实现高效的局部药物递送和细胞生长和分化的控制。将工程基质细胞-聚合物支架复合材料或无细胞胸腺再生模板植入小鼠体内,在体外和体内研究 T 细胞发育,然后分析细胞生长、分化、迁移和功能(包括抗肿瘤活性)。宿主和生物材料反应的表征还包括植入物血管化、生物材料降解和植入的炎症反应的分析。根据我使用改进的组织工程方法和优化设计、生物材料特性和细胞-生物材料相互作用的初步数据,我预计组织工程人工胸腺微环境的植入将增强 T 细胞免疫力,并有助于肿瘤免疫监视。在这个职业发展奖的帮助下,我未来五年的目标是使自己成为儿科血液学/肿瘤学领域的医师科学家,并在学术中心获得终身职位。作为一名医师科学家,我希望将临床和教学活动与独立的基于实验室的研究项目结合起来,重点关注临床相关和转化研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Johannes Zakrzewski其他文献
Johannes Zakrzewski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Johannes Zakrzewski', 18)}}的其他基金
Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells
利用造血干细胞衍生的初始 CAR T 细胞利用胸腺来长期控制肿瘤
- 批准号:
10365031 - 财政年份:2022
- 资助金额:
$ 12.77万 - 项目类别:
Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells
利用造血干细胞衍生的初始 CAR T 细胞利用胸腺来长期控制肿瘤
- 批准号:
10580801 - 财政年份:2022
- 资助金额:
$ 12.77万 - 项目类别:
Strategies to enhance thymus-independent T cell development in cancer patients
增强癌症患者胸腺独立 T 细胞发育的策略
- 批准号:
8318100 - 财政年份:2011
- 资助金额:
$ 12.77万 - 项目类别:
Strategies to enhance thymus-independent T cell development in cancer patients
增强癌症患者胸腺独立 T 细胞发育的策略
- 批准号:
8699163 - 财政年份:2011
- 资助金额:
$ 12.77万 - 项目类别:
Strategies to enhance thymus-independent T cell development in cancer patients
增强癌症患者胸腺独立 T 细胞发育的策略
- 批准号:
8891380 - 财政年份:2011
- 资助金额:
$ 12.77万 - 项目类别:
Strategies to enhance thymus-independent T cell development in cancer patients
增强癌症患者胸腺独立 T 细胞发育的策略
- 批准号:
8165831 - 财政年份:2011
- 资助金额:
$ 12.77万 - 项目类别:
相似国自然基金
单核细胞产生S100A8/A9放大中性粒细胞炎症反应调控成人Still病发病及病情演变的机制研究
- 批准号:82373465
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
成人型弥漫性胶质瘤患者语言功能可塑性研究
- 批准号:82303926
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
- 批准号:82302160
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SERPINF1/SRSF6/B7-H3信号通路在成人B-ALL免疫逃逸中的作用及机制研究
- 批准号:82300208
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于动态信息的深度学习辅助设计成人脊柱畸形手术方案的研究
- 批准号:82372499
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia
项目 4:现成的工程化脐带血自然杀伤细胞,用于治疗急性淋巴细胞白血病
- 批准号:
10931069 - 财政年份:2023
- 资助金额:
$ 12.77万 - 项目类别:
Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells
利用造血干细胞衍生的初始 CAR T 细胞利用胸腺来长期控制肿瘤
- 批准号:
10365031 - 财政年份:2022
- 资助金额:
$ 12.77万 - 项目类别:
Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells
利用造血干细胞衍生的初始 CAR T 细胞利用胸腺来长期控制肿瘤
- 批准号:
10580801 - 财政年份:2022
- 资助金额:
$ 12.77万 - 项目类别:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
评估天然和 3D 打印同种异体移植物中不同人类细胞类型的免疫原性和抗原性
- 批准号:
10353416 - 财政年份:2021
- 资助金额:
$ 12.77万 - 项目类别:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
评估天然和 3D 打印同种异体移植物中不同人类细胞类型的免疫原性和抗原性
- 批准号:
10194232 - 财政年份:2021
- 资助金额:
$ 12.77万 - 项目类别: